SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel GPR40 Agonists

Dong-Oh Yoon,^{†,||} Xiaodi Zhao,^{†,||} Dohyun Son,[†] Jung Tae Han,[‡] Jaesook Yun,^{‡,||} Dongyun Shin,[§] and Hyun-Ju Park^{*,†}[†]School of Pharmacy and [‡]Department of Chemistry, Sungkyunkwan University, Suwon 16419, South Korea[§]College of Pharmacy, Gachon University, Incheon 21936, South Korea

Supporting Information

ABSTRACT: G-protein coupled receptor 40 (GPR40) has been considered to be an attractive drug target for the treatment of type 2 diabetes because of its role in free fatty acids-mediated enhancement of glucose-stimulated insulin secretion (GSIS) from pancreatic β -cells. A series of indole-5-propanoic acid compounds were synthesized, and their GPR40 agonistic activities were evaluated by nuclear factor of activated T-cells reporter assay and GSIS assay in the MIN-6 insulinoma cells. Three compounds, **8h** (EC₅₀ = 58.6 nM), **8i** (EC₅₀ = 37.8 nM), and **8o** (EC₅₀ = 9.4 nM), were identified as potent GPR40 agonists with good GSIS effects.

KEYWORDS: GPR40 agonists, indole-5-propanoic acid, NFAT reporter assay, glucose-stimulated insulin secretion (GSIS)

Free fatty acids (FFAs) are an important source of energy for the body and play a role in signal transduction for insulin secretion and other cellular effects.^{1,2} G-protein coupled receptor 40 (GPR40) was identified as an orphan G-protein coupled receptor with an unknown function.² Recent studies revealed that GPR40 is abundantly expressed in the pancreas and regulates insulin secretion from beta cells of the pancreas via long-chain FFAs.³ Takeda has developed the GPR40 agonist TAK875 (Figure 1), which activates the glucagon-like peptide-1 (GLP-1) pathway as well as GPR40 and increases the secretion of insulin.⁴ In 2011, a phase III clinical trial of TAK875 was initiated.^{5,6} The trial was the first attempt to develop a GPR40 agonist as a drug for type 2 diabetes mellitus. However, its development was discontinued due to potential hepatotoxicity.⁷ Clinical developments of some other GPR40 agonists were also

discontinued for undisclosed reasons. Recent studies suggested that the potential liver toxicity of TAK875 and other GPR40 agonists is associated with their analogous hydrophobic pharmacophore. Smaller and less lipophilic compounds have improved the drug-likeness properties.^{8,9} As shown in Figure 1, the common feature of most GPR40 agonists is a phenyl propanoic acid group and a benzyloxy or benzyl amine group in the linker unit,^{10–15} which are very important for the GPR40 agonistic effect.^{16–18} The GPR40 agonist TUG-770 has a rigid alkyne group in the linker part,¹⁰ which should provide a different ligand receptor binding interaction compared to flexible benzyloxy or amino linker.¹⁹

Another GPR40 agonist includes a derivative of benzofuran that was designed as a constrained planar derivative of benzyloxy linker. Its agonistic activity is weaker than other derivatives having benzyloxy or alkyne moieties in the linker part.²⁰ In a similar way to develop TAK875, various bicyclic acid moieties including 2-(1*H*-indol-1-yl)acetic acid or 3-(1*H*-indol-1-yl)acetic acid are adopted in the acid tail part of GPR40 agonists with benzyloxy linker. However, their activities are weaker than those with a phenyl propanoic acid tail (EC₅₀ values ranging between 1 and 10 μ M).²¹ Based on these reports, we designed novel GPR40 agonists by employing an indole moiety in which a phenyl ring is fused to a pyrrole ring as a bioisostere of two-atom linker unit²² and a small-size aryl

Figure 1. Reported GPR40 agonists.

Received: November 6, 2017

Accepted: November 21, 2017

Published: November 21, 2017

group to reduce the hydrophobicity (Figure 2). A series of 3-(2-aryl-1H-indol-5-yl) propanoic acid derivatives was prepared for

Figure 2. Design of indole propanoic acid.

the present structure–activity relationship study. We expected binding modes of these molecules would be similar to that of TAK875 to give an agonistic effect on GPR40,²³ although their indole linker unit is more rigid than the benzyloxy linker.

The synthesis of key intermediate **5** was achieved as shown in Scheme 1. The esterification of commercially available 3-(4-

Scheme 1^a

^aReagents and Conditions: (a) sulfuric acid, EtOH, reflux, 98%; (b) NIS, DMF, r.t., 90%; (c) TMS-acetylene, PdCl₂(PPh₃)₂, CuI, TEA, THF, 60 °C, 73%; (d) TBAF (1 M in THF), THF, r.t., 82%.

aminophenyl) propanoic acid **1** under sulfuric acid provided compound **2**. To prepare 2-ethynylaniline **5**, the iodination of compound **2** was carried out first. The Sonogashira coupling reaction was conducted to replace the iodo group with ethynyl group (compound **4**) and then followed by TMS (trimethylsilyl ether) deprotection using TBAF (tetrabutylammonium fluoride) directly to afford compound **5**. Compound **5** is an important intermediate for the synthesis of indole propanoic acid derivatives, as presented in Scheme 2, because it can employ various aryl or alkyl groups at the C2 position of indole ring. Among the various methods for the synthesis of indole, we used a method that cyclizes the acetylenic substituent onto the amino group.

Scheme 2^a

^aReagents and Conditions: (a) aryl halide, PdCl₂(PPh₃)₂, CuI, TEA, DMF, 80 °C; (b) AuCl₃, EtOH, 60 °C; (c) NaOH, MeOH, 40 °C.

The synthesis of indole propanoic acid derivative was accomplished as summarized in Scheme 2. Various phenyl groups were introduced to the key intermediate **5** by the Sonogashira reaction. In this reaction, the bulkiness of the ortho-substituent of aryl halide affected the yield, and the diyne compound was obtained as a main side product. For the synthesis of indole, gold chloride (AuCl₃) was used, and the indole compound **7** was easily obtained under mild reaction conditions.²⁴ Finally, the resulting indole compounds were hydrolyzed to give the final products, **8a–8r**.

We conducted a nuclear factor of activated T-cells (NFAT)-luciferase reporter assay²⁶ in Chinese hamster ovary (CHO) cells to evaluate the GPR40 agonistic activities of the compounds in comparison with TAK875, respectively (Figure S1 in the Supporting Information). Our reporter assay system was validated using the reference molecule TAK875, giving the EC₅₀ value of 14 nM (Table 1), which is similar to that from

Table 1. 2-Aryl Substituted Indole Propanoic Acid

Compd	R	EC ₅₀ (nM, hFFA1) ^a	ALog P ^b	PPAR γ at 10 μM ^c
TAK875		14	5.06	
8a		N.A.	3.65	14%
8b		447	4.14	4%
8c		N.A.	4.14	8%
8d		N.A.	4.14	4%
8e		N.A.	3.63	0%
8f		N.A.	3.63	5%
8g		N.A.	3.63	5%
8h		54.6	4.31	1%
8i		37.8	4.31	101% ^d
8j		778	4.31	1%
8k		1800	4.39	56%

^aLuciferase reporter assay. ^bALogP²⁵ was predicted by Schrödinger Maestro. ^cPercent activity compared to 1 μM rosiglitazone. ^dPPARγ EC₅₀ = 2.4 μM. N.A., no activity (>25 μM).

the calcium influx assay.¹¹ In terms of lipophilicity, the calculated logP (ALogP) values for all compounds, except **8m**, were less than that of TAK875 (5.06), indicating that hydrophobicity is reduced in indole propanoic acid derivatives as expected.

Since another antidiabetic target PPARγ is also activated by fatty acids, it is plausible that GPR40 agonists may have PPARγ

agonistic activity.²⁷ Several indole-5-acetic acid and α -alkoxy-indole-5-propionic acid derivatives, which are structurally similar to our compounds, were also reported as PPAR agonists.^{28,29} Thus, we examined the PPAR γ transactivation activity of our compounds at 10 μ M (Tables 1 and 2), and

Table 2. Effect of *Ortho*-Substituted Aryl 2-Indole Propanoic Acid

Compd	R	EC ₅₀ (nM, hFFA1) ^a	ALog P ^b	PPAR γ at 10 μ M ^c
8l		1308	4.59	8%
8m		1016	5.78	2%
8n		1207	3.86	3%
8o		9.4	4.40	4%
8p		1800	4.59	7%
8q		N.A.	4.84	2%
8r		N.A.	2.78	64%

^aLuciferase reporter assay. ^bALogP²⁵ was predicted by Schrödinger Maestro. ^cPercent activity compared to 1 μ M rosiglitazone. N.A., no activity (>25 μ M).

most of them did not show significant PPAR γ agonist activity, except **8i**. The EC₅₀ values for PPAR γ were determined for **8i**, **8k**, and **8r**, and they were 2.4, 236.4, and 56.9 μ M, respectively (Figure S2 in the Supporting Information). Although **8i** showed some PPAR γ agonist activity, it is about 60 times more selective for GPR40.

To examine the effects of substituents on the phenyl ring, the alkyl- (methyl, methoxy, ethyl, or isopropyl) substituted derivatives did not show good GPR40 agonistic activity, while the halogen substitution resulted in significant agonistic activity (Tables 1 and 2). Chloro substitution (**8h–8j**) provided good activity in the order *meta* $\approx$ *ortho* > *para*. At first, we examined if the *meta*-substitution is important for activity, *meta*-bromophenyl analogue **8k** was synthesized, but its activity was about 50-fold lower than the *meta*-chloro derivative **8i**. Therefore, we focused on the *ortho*-substitution assuming that the steric effect of the *ortho*-substituent may adjust the dihedral angle between the indole ring and the phenyl ring optimal for receptor binding (Table 2). Various *ortho*-substituted derivatives were prepared, and their agonistic effects were evaluated. Among the alkyl substituted analogues, only *o*-methyl phenyl compound **8b** showed submicromolar activity. Derivatives with *o*-CF₃ (**8l**), *o*-OCF₃ (**8m**), and *o*-F (**8n**) exhibited moderate micromolar potency. The compound having *o*-Br substituent (**8o**) showed the highest agonistic activity (EC₅₀ = 9.4 nM), while the *m*-Br derivative showed almost 200 times lower activity (Table 1). These results suggest that a substituent at the *ortho* position of the aryl group may not only be a simple steric

blocker to adjust the conformation of the ligand but may also be involved in interaction with the receptor. The halogen atom is preferred at the *ortho*-position, and the agonistic activity decreases in the order Br > Cl > F > H.

To understand the dramatic difference in GPR40 agonistic activity between *o*-Br (**8o**) and *m*-Br (**8k**) based on their binding modes, docking simulations were carried out using the X-ray structure of TAK875-GPR40 complex (pdb id 4PHU).²³ Most GPR40 agonists have a carboxylic acid moiety as a key pharmacophore. The analysis of the X-ray structure revealed a polar interaction network between the carboxylate group of TAK875 and Arg183, Arg258, Tyr91, and Tyr240, which is crucial for GPR40 agonistic activity. Likewise, in the docked models of GPR40 with **8o** and **8k** within the TAK875-binding pocket (Figure 3), the carboxylate moiety also forms hydrogen

Figure 3. Computational analysis of the binding mode of **8o** (A) and **8k** (B) in GPR40. The carboxylate moiety is highly coordinated by several key residues. Hydrogen bond interactions (<3 Å) are depicted as dashed cylinders. Gray capped sticks represent key amino acid residues within the binding site and the ribbon is the backbone of hGPR40. The binding site is rendered in MOLCAD lipophilic potential surface and colored from blue (hydrophilic) to dark brown (hydrophobic).

bonds with Arg183 and Arg258. In addition, indole N–H interacts with backbone amide carbonyl oxygen of Leu138 by forming a H-bond, suggesting that indole NH group may affect the receptor binding affinity. To verify the significance of indole NH for GPR40 agonistic effect, we prepared and tested several N-methylated indole derivatives of **8i**, **8j**, and **8o** and found that they almost lost activities with EC₅₀ > 10 μ M (**8s**, **8t**, and **8u** in the Supporting Information Table S1).

We also identified the unique Br $\cdots\pi$ interaction^{30,31} between the Br substituent of drug and Phe142 in the binding site, as a possible key factor for GPR40 agonistic activity (Figure 3A). In the binding pose of **8o**, the distance from *o*-Br to the centroid of the phenyl ring in Phe142 is 3.71 Å, and that to the nearest carbon of phenyl ring is 3.33 Å, giving a difference of 0.38 Å. Since this difference is bigger than 0.3 Å, the Br $\cdots\pi$ interaction can be formed with an “edge-on” geometry. However, for the *m*-Br analogue (**8k**), the distance from *m*-Br atom to the centroid of the phenyl ring in Phe142 is 5.25 Å (Figure 3B), and that to the nearest carbon of the phenyl ring is 4.46 Å. It means the Br $\cdots\pi$ interaction cannot be formed because both distances are longer than 4.2 Å. Thus, the Br $\cdots\pi$ interaction might contribute to provide higher binding affinity toward GPR40 for **8o**.

In most of the reported GPR40 agonists with a propanoic acid functional group, some substituents on its beta position were employed to improve the metabolic stability by avoiding β -oxidation. Therefore, we inspected a liver microsomal stability of compound **8h**, **8i**, and **8o**, and they exhibited good metabolic stability (Table 3).

Table 3. Metabolic Stability of Compounds **8h**, **8i**, and **8o**

Compd	CL _{int} (human/mouse) ^a
8h	9.2/14.3
8i	4.3/11.3
8o	7.1/10.4

^aMicrosomal stability: clearance intrinsic ($\mu\text{L}/\text{min}/\text{mg}$).

To detect insulin secretion effects of derivatives having GPR40 agonistic activity in the NFAT luciferase assay, we performed a glucose-stimulated insulin secretion (GSIS) assay in MIN6 cells.¹ The insulin secretion effect was verified at a glucose concentration of 17 mM. For compounds, **8h**, **8i**, and **8o**, insulin secretion was elevated by 1.4-, 1.7-, and 1.6-fold compared to 17 mM glucose, respectively (Figure 4).

Figure 4. Glucose-stimulated insulin secretion test of derivatives **8a**, **8h**, **8i**, and **8o** in MIN6 cells. The data is represented as the mean $\pm$ standard error ($n = 2$). ### $p \leq 0.01$ by Student's test; * $p \leq 0.05$, ** $p \leq 0.025$, *** $p \leq 0.01$ vs 17 mM glucose alone by Student's test.

Compounds **8i** and **8o** yielded GSIS effects similar to that of the reference compound TAK875 (1.7-fold). In contrast, the compound **8a** with low GPR40 agonist activity ($\text{EC}_{50} > 25 \mu\text{M}$) did not induce insulin secretion. The result suggests that the GSIS effect of **8h**, **8i**, and **8o** are related to selective GPR40 activation.

In conclusion, for development of novel GPR40 agonists, we utilized indole propanoic acid moiety as a simplified novel scaffold for a potent GPR40 agonist. Various derivatives were prepared, and their GPR40 agonistic activities were evaluated by an NFAT luciferase assay. Among these derivatives, potent GPR40 agonists were identified. These agonists, **8h**, **8i**, and **8o**, showed good microsomal stability as well as an excellent insulin secretion effect in MIN6 cells. Based on these results, we continue to perform further *in vivo* efficacy studies for the development of these GPR40 agonists as antidiabetic candidates.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmmedchemlett.7b00460.

Syntheses and characterization data for compounds **8a**–**8u**, assay protocols, and computational modeling method (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*Tel: +82-31-290-7719. E-mail: hyunju85@skku.edu.

ORCID

Jaesook Yun: 0000-0003-4380-7878

Author Contributions

[†]These authors contributed equally to this work.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2014R1A2A1A11050892).

■ REFERENCES

- (1) Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; Tanaka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Komatsu, H.; Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; Fujisawa, Y.; Fujino, M. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40. *Nature* **2003**, 422 (6928), 173–176.
- (2) Briscoe, C. P.; Tadayyon, M.; Andrews, J. L.; Benson, W. G.; Chambers, J. K.; Eilert, M. M.; Ellis, C.; Elshourbagy, N. A.; Goetz, A. S.; Minnick, D. T.; Murdock, P. R.; Sauls, H. R., Jr.; Shabon, U.; Spinage, L. D.; Strum, J. C.; Szekeres, P. G.; Tan, K. B.; Way, J. M.; Ignar, D. M.; Wilson, S.; Muir, A. I. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. *J. Biol. Chem.* **2003**, 278 (13), 11303–11.
- (3) Nagasumi, K.; Esaki, R.; Iwachidow, K.; Yasuhara, Y.; Ogi, K.; Tanaka, H.; Nakata, M.; Yano, T.; Shimakawa, K.; Taketomi, S.; Takeuchi, K.; Odaka, H.; Kaisho, Y. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. *Diabetes* **2009**, 58 (5), 1067–76.
- (4) Tsujihata, Y.; Ito, R.; Suzuki, M.; Harada, A.; Negoro, N.; Yasuma, T.; Momose, Y.; Takeuchi, K. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. *J. Pharmacol. Exp. Ther.* **2011**, 339 (1), 228–37.

- (5) Poutout, V.; Lin, D. C. Modulating GPR40: therapeutic promise and potential in diabetes. *Drug Discovery Today* **2013**, *18* (23–24), 1301–8.
- (6) Yabuki, C.; Komatsu, H.; Tsujihata, Y.; Maeda, R.; Ito, R.; Matsuda-Nagasumi, K.; Sakuma, K.; Miyawaki, K.; Kikuchi, N.; Takeuchi, K.; Habata, Y.; Mori, M. A novel antidiabetic drug, fasiglifam/TAK-875, acts as an allosteric modulator of FFAR1. *PLoS One* **2013**, *8* (10), e76280.
- (7) Wolinski, F. S.; Zhu, A. Z. X.; Johnson, M.; Yu, S.; Moriya, Y.; Ebihara, T.; Csizmadia, V.; Grieves, J.; Paton, M.; Liao, M.; Gemski, C.; Pan, L.; Vakilynejad, M.; Dragan, Y. P.; Chowdhury, S. K.; Kirby, P. J. Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury. *Toxicol. Sci.* **2017**, *157* (1), 50–61.
- (8) Li, X.; Zhong, K.; Guo, Z.; Zhong, D.; Chen, X. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury. *Drug Metab. Dispos.* **2015**, *43* (11), 1751–9.
- (9) Hauge, M.; Vestmar, M. A.; Husted, A. S.; Ekberg, J. P.; Wright, M. J.; Di Salvo, J.; Weinglass, A. B.; Engelstoft, M. S.; Madsen, A. N.; Luckmann, M.; Miller, M. W.; Trujillo, M. E.; Frimurer, T. M.; Holst, B.; Howard, A. D.; Schwartz, T. W. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo. *Mol. Metab.* **2015**, *4* (1), 3–14.
- (10) Christiansen, E.; Hansen, S. V.; Urban, C.; Hudson, B. D.; Wargent, E. T.; Grundmann, M.; Jenkins, L.; Zaibi, M.; Stocker, C. J.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Milligan, G.; Cawthorne, M. A.; Ulven, T. Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. *ACS Med. Chem. Lett.* **2013**, *4* (5), 441–445.
- (11) Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. *ACS Med. Chem. Lett.* **2010**, *1* (6), 290–4.
- (12) Houze, J. B.; Zhu, L.; Sun, Y.; Akerman, M.; Qiu, W.; Zhang, A. J.; Sharma, R.; Schmitt, M.; Wang, Y.; Liu, J.; Medina, J. C.; Reagan, J. D.; Luo, J.; Tonn, G.; Zhang, J.; Lu, J. Y.; Chen, M.; Lopez, E.; Nguyen, K.; Yang, L.; Tang, L.; Tian, H.; Shuttleworth, S. J.; Lin, D. C. AMG 837: a potent, orally bioavailable GPR40 agonist. *Bioorg. Med. Chem. Lett.* **2012**, *22* (2), 1267–70.
- (13) Costanzi, S.; Neumann, S.; Gershengorn, M. C. Seven transmembrane-spanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: pharmacological, phylogenetic, and drug discovery aspects. *J. Biol. Chem.* **2008**, *283* (24), 16269–73.
- (14) Takano, R.; Yoshida, M.; Inoue, M.; Honda, T.; Nakashima, R.; Matsumoto, K.; Yano, T.; Ogata, T.; Watanabe, N.; Hirouchi, M.; Yoneyama, T.; Ito, S.; Toda, N. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist. *ACS Med. Chem. Lett.* **2015**, *6* (3), 266–70.
- (15) Hamdouchi, C.; Kahl, S. D.; Patel Lewis, A.; Cardona, G. R.; Zink, R. W.; Chen, K.; Eessalu, T. E.; Ficorilli, J. V.; Marcelo, M. C.; Otto, K. A.; Wilbur, K. L.; Lineswala, J. P.; Piper, J. L.; Coffey, D. S.; Sweetana, S. A.; Haas, J. V.; Brooks, D. A.; Pratt, E. J.; Belin, R. M.; Deeg, M. A.; Ma, X.; Cannady, E. A.; Johnson, J. T.; Yumibe, N. P.; Chen, Q.; Maiti, P.; Montrose-Rafizadeh, C.; Chen, Y.; Reifel Miller, A. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). *J. Med. Chem.* **2016**, *59* (24), 10891–10916.
- (16) Chen, C.; Li, H.; Long, Y. Q. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space. *Bioorg. Med. Chem. Lett.* **2016**, *26* (23), 5603–5612.
- (17) Krasavin, M.; Lukin, A.; Zhurilo, N.; Kovalenko, A.; Zahanich, I.; Zozulya, S.; Moore, D.; Tikhonova, I. G. Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold. *Bioorg. Med. Chem.* **2016**, *24* (13), 2954–2963.
- (18) Tikhonova, I. G.; Sum, C. S.; Neumann, S.; Engel, S.; Raaka, B. M.; Costanzi, S.; Gershengorn, M. C. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. *J. Med. Chem.* **2008**, *51* (3), 625–33.
- (19) Christiansen, E.; Urban, C.; Grundmann, M.; Due-Hansen, M. E.; Hagesaether, E.; Schmidt, J.; Pardo, L.; Ullrich, S.; Kostenis, E.; Kassack, M.; Ulven, T. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. *J. Med. Chem.* **2011**, *54* (19), 6691–703.
- (20) Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Merten, N.; Pfeleiderer, M.; Karlsen, K. K.; Rasmussen, S. S.; Steensgaard, M.; Hamacher, A.; Schmidt, J.; Drewke, C.; Petersen, R. K.; Kristiansen, K.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Ulven, T. Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469. *ACS Med. Chem. Lett.* **2010**, *1* (7), 345–9.
- (21) Sharma, R.; Akerman, M.; Cardozo, M. G.; Houze, J. B.; Li, A.; Liu, J. Q.; Liu, J. W.; Ma, Z. H.; Medina, J. C.; Schmitt, J. M.; Sun, Y.; Wang, Y. C.; Wang, Z. Y.; Zhu, L. S. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders. Patent WO 2007106469 A2, 2007.
- (22) Kaushik, N. K.; Kaushik, N.; Attri, P.; Kumar, N.; Kim, C. H.; Verma, A. K.; Choi, E. H. Biomedical importance of indoles. *Molecules* **2013**, *18* (6), 6620–62.
- (23) Srivastava, A.; Yano, J.; Hirozane, Y.; Kefala, G.; Gruswitz, F.; Snell, G.; Lane, W.; Ivetac, A.; Aertgeerts, K.; Nguyen, J.; Jennings, A.; Okada, K. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. *Nature* **2014**, *513* (7516), 124–7.
- (24) Majumdar, K. C.; Samanta, S.; Chattopadhyay, B. A convenient synthesis of pyrrolopyridines and 2-substituted indoles by gold-catalyzed cycloisomerization. *Tetrahedron Lett.* **2008**, *49* (50), 7213–7216.
- (25) Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J. Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods. *J. Phys. Chem. A* **1998**, *102* (21), 3762–3772.
- (26) Sheth, H.; Gorey, C.; Roush, N.; Smallman, S.; Collantes, E.; Santoro, M.; Olson, B.; Fitzgerald, L.; Lee, P. H.; Shen, X. J. A Multiplexed Fluorescent Calcium and NFAT Reporter Gene Assay to Identify GPCR Agonists. *Curr. Chem. Genomics Transl. Med.* **2013**, *7*, 1–8.
- (27) Smith, N. J.; Stoddart, L. A.; Devine, N. M.; Jenkins, L.; Milligan, G. The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. *J. Biol. Chem.* **2009**, *284* (26), 17527–39.
- (28) Adams, A. D.; von Langen, D.; Richard, L.; Tolman; Koyama, H. Antidiabetic agents. Patent WO 199827974 A1, 1998.
- (29) Bhuruth-Alcor, Y.; Rost, T.; Jorgensen, M. R.; Kontogiorgis, C.; Skorge, J.; Cooper, R. G.; Sheridan, J. M.; Hamilton, W. D.; Heal, J. R.; Berge, R. K.; Miller, A. D. Synthesis of novel PPAR α /gamma dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD. *Org. Biomol. Chem.* **2011**, *9* (4), 1169–88.
- (30) Imai, Y. N.; Inoue, Y.; Nakanishi, I.; Kitaura, K. Cl-pi interactions in protein-ligand complexes. *Protein Sci.* **2008**, *17* (7), 1129–37.
- (31) Matter, H.; Nazare, M.; Gussregen, S.; Will, D. W.; Schreuder, H.; Bauer, A.; Urmann, M.; Ritter, K.; Wagner, M.; Wehner, V. Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity. *Angew. Chem., Int. Ed.* **2009**, *48* (16), 2911–6.